title: Atopic dermatitis successfully treated by eradication of Helicobacter pylori.
abstract: A relationship between allergic diseases and Helicobacter pylori infection has recently been noted. We report a case of atopic dermatitis and H. pylori infection in a 14-year-old girl. She had had widespread diffuse skin erythema with erosions and pigmentation since the age of 3 years. Endoscopically, there was chronic antral gastritis with H. pylori infection and histological eosinophilic infiltration. A high titer of H. pylori-specific IgG was present in serum. She was treated with a proton pump inhibitor (lansoprazole 60 mg), an antibiotic (clarithromycin 800 mg), and plaunotol (a mucosal protective agent, 480 mg) for 2 weeks to eliminate the infection. After 10 days of treatment, erythema and itching were more widespread and vesicle formation was seen on the foot. Generalized skin lesions abated a few days later. After eradication of the bacterium by the treatment, eosinophils decreased from 38.8% to 19.0%, and the clinical signs of atopic dermatitis almost disappeared. Serum gastrin level and the pepsinogen I/II ratio were normalized and histological findings of gastric mucosa showed improvement. H. pylori-specific IgE antibody, analyzed by the Western blot method, gradually decreased with the eradication treatment.
authors.affiliation: Second Department of Internal Medicine, Oita Medical University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Fujioka
authors.forename: A
authors.initials: A
authors.lastname: Nishizono
authors.forename: J
authors.initials: J
authors.lastname: Nagai
authors.forename: M
authors.initials: M
authors.lastname: Tokieda
authors.forename: R
authors.initials: R
authors.lastname: Kodama
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Nasu
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D015153:Blotting, Western; D017291:Clarithromycin / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000382:microbiology*; D004224:Diterpenes; D004359:Drug Therapy, Combination; D005233:Fatty Alcohols / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology*; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D054328:Proton Pump Inhibitors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D005233:Fatty Alcohols; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D017291:Clarithromycin; D009853:Omeprazole; C047686:plaunotol